MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.31629

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025

Percutaneous Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Reconstructed Time-to-Event Data.

Ghaly Ramy, Amin Ahmed Mazen, Kim Samuel, Taha Hosam I, Elgendy Mohamed S, Rmilah Anan Abu, Abuelazm Mohamed, Khan Mirza S

СтатьяСистематический обзорМетаанализПеревод пока не подготовлен

Аннотация

BACKGROUND

Mitral transcatheter edge-to-edge repair (TEER) is approved for patients with severe functional mitral regurgitation (FMR) beyond optimal medical therapy (OMT).

AIMS: We aimed to assess TEER's efficacy beyond OMT in patients with severe FMR.

METHODS

A systematic review and meta-analysis were conducted, including randomized controlled trials from PubMed, Cochrane, Scopus, and EMBASE up to September 2024.

PRIMARY OUTCOME: heart failure hospitalization (HFH); secondary outcomes: cardiovascular (CV) mortality, all-cause mortality, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Time-to-event data from Kaplan-Meier curves were reconstructed for individual patient data.

RESULTS

Three studies (1423 patients) were included. TEER significantly reduced HFH (RR 0.73, 95% CI 0.58-0.92, p < 0.01) and CV mortality (RR 0.79, 95% CI 0.66-0.95, p = 0.01), and improved KCCQ scores (mean difference 14.32, 95% CI 10.85-17.80, p < 0.01) compared to OMT. No significant difference was found for all-cause mortality (RR 0.80, 95% CI 0.63-1.02, p = 0.07). Prognostic meta-analysis showed a 34% reduced risk of HFH (HR 0.66, 95% CI 0.45-0.96, p = 0.03), but no effect on all-cause or CV mortality. Reconstructed Kaplan-Meier analysis confirmed a 34% reduced risk of HFH (HR 0.65, p < 0.001), with effect attenuation after 15 months in landmark analysis (HR 0.64, p = 0.07). RMST analysis showed a 2.9-month longer HFH-free survival with TEER (p < 0.01).

CONCLUSION

In patients with FMR, TEER significantly reduces HFH, improves functional status, and lowers CV mortality at 24 months but does not significantly affect all-cause mortality. The device group experienced a modest, but significant, 2.9-month longer HFH-free survival compared to the control group. However, the reduction in HFH showed attenuation beyond 15 months.

Для цитирования: Ghaly Ramy, Amin Ahmed Mazen, Kim Samuel, Taha Hosam I, Elgendy Mohamed S, Rmilah Anan Abu, Abuelazm Mohamed, Khan Mirza S. Percutaneous Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Reconstructed Time-to-Event Data.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2025. DOI: 10.1002/ccd.31629.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.